The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
This study is currently recruiting participants.
Verified April 2013 by AbbVie
Sponsor:
AbbVie (prior sponsor, Abbott)
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01506609
First received: January 6, 2012
Last updated: April 4, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with locally recurrent Breast Cancer not amenable to therapy with curative intent, or metastatic breast cancer and a documented (BRCA1) and (BRCA2) deleterious germline mutation:
| Condition | Intervention | Phase |
|---|---|---|
|
Metastatic Breast Cancer |
Drug: Veliparib Drug: Temozolomide Drug: Carboplatin Drug: Paclitaxel Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer |
Resource links provided by NLM:
Further study details as provided by AbbVie:
Primary Outcome Measures:
- Progression -Free Survival [ Time Frame: Radiographic evaluation every 9 weeks, clinical evaluation every cycle ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Overall Survival [ Time Frame: From Cycle 1 Day 1 until patient's death or 3 years post discontinuation ] [ Designated as safety issue: No ]
- Clinical Benefit Rate (CBR) [ Time Frame: From Cycle 1 Day1 until patient's death or 3 years post discontinuation ] [ Designated as safety issue: No ]
- Objective Response Rate [ Time Frame: From Cycle 1 Day 1 until patient's death or 3 years post discontinuation ] [ Designated as safety issue: No ]
Other Outcome Measures:
- Chemotherapy-Induced Peripheral Neuropathy (CIPN) [ Time Frame: From Cycle 1 Day 1 for subjects on the carboplatin and paclitaxel treatment arm, through 30 Day Follow-up Visit. ] [ Designated as safety issue: No ]CIPN (as assessed by the EORTC QLQ-CIPN20 questionnaire and NCI-CTCAE 4.0 grading for peripheral neuropathy
| Estimated Enrollment: | 255 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | May 2015 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Veliparib with Temozolomide
Veliparib on Day 1 thru 7 and temozolomide on Day 1 thru 5 of a 28-day cycle.
|
Drug: Veliparib
Days 1 through 7 of 28-day cycle (in combination with Temozolomide) or Days 1 through 7 of 21-day cycle (in combination with Carboplatin and Paclitaxel).
Other Name: ABT-888
Drug: Temozolomide
Days 1 through 5 of 28-day cycle (in combination with veliparib).
Other Name: Temodal
|
|
Experimental: Veliparib with Carboplatin and Paclitaxel
Veliparib on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
|
Drug: Veliparib
Days 1 through 7 of 28-day cycle (in combination with Temozolomide) or Days 1 through 7 of 21-day cycle (in combination with Carboplatin and Paclitaxel).
Other Name: ABT-888
Drug: Carboplatin
Day 3 of 21-day cycle
Drug: Paclitaxel
Day 3 of 21-day cycle.
Other Name: Taxol
|
|
Placebo Comparator: Placebo with Carboplatin and Paclitaxel
Placebo on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
|
Drug: Carboplatin
Day 3 of 21-day cycle
Drug: Paclitaxel
Day 3 of 21-day cycle.
Other Name: Taxol
Drug: Placebo
Placebo comparator for Veliparib days 1 through 7 of 21-day cycle (in combination with carboplatin and/or paclitaxel).
|
Detailed Description:
Subjects will be randomized in a 1:1:1 ratio to one of the three treatment groups. The safety of each treatment group will be assessed by evaluating study drug exposure, adverse events, serious adverse events, all deaths, changes in laboratory determinations, and vital sign parameters. The Clinical Benefit Rate (CBR) and Objective Response Rate (ORR) as well as Progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be assessed. Study visits will be conducted according to the protocol schedule and randomization group. Study visits will include physical examination, laboratory blood sample collection, and assessment of vital signs, medical history and urinalysis. 12-lead Electrocardiogram (ECG) will be performed at protocol specified visits.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18 years of age, male and female.
- Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.
- Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
- Must have a documented deleterious Breast Cancer Gene BRCA1 or BRCA2 germline mutation.
- If Human Epidermal Growth Factor Receptor (HER2) positive, subjects must have received and progressed on at least one prior standard HER2 directed therapy or the subject must be ineligible to receive anti-HER2 therapy.
- Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.
- Subject must have adequate bone marrow, renal and hepatic function.
- Subject must not be pregnant or plan to conceive a child.
Exclusion Criteria:
- Received anticancer agent(s) or an investigational agent within 21 days prior to C1D1, or radiotherapy within 28 days prior Cycle 1 Day 1
- More than 2 prior lines of cytotoxic chemotherapy
- Prior treatment of breast cancer with temozolomide, a platinum agent, or a Poly (ADP ribose) Polymerase (PARP) inhibitor.
- Prior taxane therapy for metastatic breast cancer.
- A history of or evidence of brain metastases or leptomeningeal disease.
- A history of uncontrolled seizure disorder
- Pre-existing neuropathy from any cause in excess of Grade 1
- Known history of allergic reaction to cremophor/paclitaxel
- Clinical significant uncontrolled conditions â€" active infection, myocardial infarction, stroke, or transient ischemic attack, psychiatric illness/social situations that would limit compliance.
- Pregnant or breastfeeding
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01506609
Hide Study Locations
Contacts
| Contact: Raymond A. Knight, BS | (847) 938-1378 | raymond.knight@abbvie.com |
| Contact: Anglea M. Deluca, BS | (847) 936-3354 | angela.deluca@abbvie.com |
Hide Study LocationsLocations
| United States, Alabama | |
| Site Reference ID/Investigator# 62994 | Recruiting |
| Birmingham, Alabama, United States, 35249-3300 | |
| Principal Investigator: Site Reference ID/Investigator# 62994 | |
| United States, Arkansas | |
| Site Reference ID/Investigator# 60750 | Recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| Principal Investigator: Site Reference ID/Investigator# 60750 | |
| United States, California | |
| Site Reference ID/Investigator# 60754 | Recruiting |
| La Jolla, California, United States, 92093-0698 | |
| Principal Investigator: Site Reference ID/Investigator# 60754 | |
| Site Reference ID/Investigator# 60743 | Recruiting |
| Los Angeles, California, United States, 90025 | |
| Principal Investigator: Site Reference ID/Investigator# 60743 | |
| Site Reference ID/Investigator# 60760 | Recruiting |
| Los Angeles, California, United States, 90048 | |
| Principal Investigator: Site Reference ID/Investigator# 60760 | |
| Site Reference ID/Investigator# 65488 | Recruiting |
| Stanford, California, United States, 94305-5826 | |
| Principal Investigator: Site Reference ID/Investigator# 65488 | |
| United States, Colorado | |
| Site Reference ID/Investigator# 60751 | Recruiting |
| Aurora, Colorado, United States, 80045 | |
| Principal Investigator: Site Reference ID/Investigator# 60751 | |
| United States, Florida | |
| Site Reference ID/Investigator# 60749 | Recruiting |
| Boca Raton, Florida, United States, 33486 | |
| Principal Investigator: Site Reference ID/Investigator# 60749 | |
| Site Reference ID/Investigator# 62995 | Recruiting |
| Fort Lauderdale, Florida, United States, 33308 | |
| Principal Investigator: Site Reference ID/Investigator# 62995 | |
| Site Reference ID/Investigator# 60746 | Recruiting |
| Tampa, Florida, United States, 33612 | |
| Principal Investigator: Site Reference ID/Investigator# 60746 | |
| Site Reference ID/Investigator# 60762 | Recruiting |
| West Palm Beach, Florida, United States, 33401 | |
| Principal Investigator: Site Reference ID/Investigator# 60762 | |
| United States, Illinois | |
| Site Reference ID/Investigator# 65489 | Recruiting |
| Chicago, Illinois, United States, 60612 | |
| Principal Investigator: Site Reference ID/Investigator# 65489 | |
| Site Reference ID/Investigator# 60755 | Recruiting |
| Chicago, Illinois, United States, 60611 | |
| Principal Investigator: Site Reference ID/Investigator# 60755 | |
| Site Reference ID/Investigator# 60757 | Recruiting |
| Chicago, Illinois, United States, 60637-1470 | |
| Principal Investigator: Site Reference ID/Investigator# 60757 | |
| Site Reference ID/Investigator# 60744 | Recruiting |
| Zion, Illinois, United States, 60099 | |
| Principal Investigator: Site Reference ID/Investigator# 60744 | |
| United States, Maryland | |
| Site Reference ID/Investigator# 60748 | Recruiting |
| Baltimore, Maryland, United States, 21202 | |
| Principal Investigator: Site Reference ID/Investigator# 60748 | |
| Site Reference ID/Investigator# 60759 | Recruiting |
| Baltimore, Maryland, United States, 21231 | |
| Principal Investigator: Site Reference ID/Investigator# 60759 | |
| Site Reference ID/Investigator# 91213 | Recruiting |
| Baltimore, Maryland, United States, 21231 | |
| Principal Investigator: Site Reference ID/Investigator# 91213 | |
| Site Reference ID/Investigator# 92633 | Recruiting |
| Baltimore, Maryland, United States, 21231 | |
| Principal Investigator: Site Reference ID/Investigator# 92633 | |
| United States, Massachusetts | |
| Site Reference ID/Investigator# 64582 | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: Site Reference ID/Investigator# 64582 | |
| United States, Michigan | |
| Site Reference ID/Investigator# 71193 | Recruiting |
| Lansing, Michigan, United States, 48912 | |
| Principal Investigator: Site Reference ID/Investigator# 71193 | |
| United States, Missouri | |
| Site Reference ID/Investigator# 62724 | Recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Principal Investigator: Site Reference ID/Investigator# 62724 | |
| United States, New Jersey | |
| Site Reference ID/Investigator# 62783 | Recruiting |
| New Brunswick, New Jersey, United States, 08901 | |
| Principal Investigator: Site Reference ID/Investigator# 62783 | |
| United States, New York | |
| Site Reference ID/Investigator# 60756 | Recruiting |
| New York, New York, United States, 10003 | |
| Principal Investigator: Site Reference ID/Investigator# 60756 | |
| Site Reference ID/Investigator# 63222 | Recruiting |
| New York, New York, United States, 10021 | |
| Principal Investigator: Site Reference ID/Investigator# 63222 | |
| Site Reference ID/Investigator# 87973 | Recruiting |
| New York, New York, United States, 10003 | |
| Principal Investigator: Site Reference ID/Investigator# 87973 | |
| Site Reference ID/Investigator# 87993 | Recruiting |
| New York, New York, United States, 10003 | |
| Principal Investigator: Site Reference ID/Investigator# 87993 | |
| United States, North Carolina | |
| Site Reference ID/Investigator# 60747 | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Principal Investigator: Site Reference ID/Investigator# 60747 | |
| United States, Pennsylvania | |
| Site Reference ID/Investigator# 62723 | Recruiting |
| Hershey, Pennsylvania, United States, 17033-0850 | |
| Principal Investigator: Site Reference ID/Investigator# 62723 | |
| Site Reference ID/Investigator# 60753 | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: Site Reference ID/Investigator# 60753 | |
| Site Reference ID/Investigator# 60758 | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Principal Investigator: Site Reference ID/Investigator# 60758 | |
| United States, South Carolina | |
| Site Reference ID/Investigator# 60752 | Recruiting |
| Charleston, South Carolina, United States, 29425 | |
| Principal Investigator: Site Reference ID/Investigator# 60752 | |
| United States, Tennessee | |
| Site Reference ID/Investigator# 65487 | Recruiting |
| Memphis, Tennessee, United States, 38120 | |
| Principal Investigator: Site Reference ID/Investigator# 65487 | |
| United States, Texas | |
| Site Reference ID/Investigator# 60745 | Recruiting |
| Dallas, Texas, United States, 75390-9063 | |
| Principal Investigator: Site Reference ID/Investigator# 60745 | |
| Site Reference ID/Investigator# 60742 | Recruiting |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: Site Reference ID/Investigator# 60742 | |
| United States, Utah | |
| Site Reference ID/Investigator# 62722 | Recruiting |
| Salt Lake City, Utah, United States, 84112 | |
| Principal Investigator: Site Reference ID/Investigator# 62722 | |
| Australia | |
| Site Reference ID/Investigator# 63280 | Recruiting |
| Adelaide, Australia, SA 5000 | |
| Principal Investigator: Site Reference ID/Investigator# 63280 | |
| Site Reference ID/Investigator# 63272 | Recruiting |
| East Melbourne, Australia, 3002 | |
| Principal Investigator: Site Reference ID/Investigator# 63272 | |
| Site Reference ID/Investigator# 63279 | Recruiting |
| Hobart, Australia, 7000 | |
| Principal Investigator: Site Reference ID/Investigator# 63279 | |
| Site Reference ID/Investigator# 63276 | Recruiting |
| Milton, Australia, 4064 | |
| Principal Investigator: Site Reference ID/Investigator# 63276 | |
| Site Reference ID/Investigator# 63278 | Recruiting |
| Parkville, Australia, 3050 | |
| Principal Investigator: Site Reference ID/Investigator# 63278 | |
| Site Reference ID/Investigator# 65262 | Recruiting |
| Perth, Australia, 6000 | |
| Principal Investigator: Site Reference ID/Investigator# 65262 | |
| Site Reference ID/Investigator# 63271 | Recruiting |
| Randwick, Australia, 2031 | |
| Principal Investigator: Site Reference ID/Investigator# 63271 | |
| Site Reference ID/Investigator# 63273 | Recruiting |
| Westmead, Australia, 2145 | |
| Principal Investigator: Site Reference ID/Investigator# 63273 | |
| Site Reference ID/Investigator# 63274 | Recruiting |
| Wollongong, Australia, 2500 | |
| Principal Investigator: Site Reference ID/Investigator# 63274 | |
| Canada | |
| Site Reference ID/Investigator# 67862 | Recruiting |
| Montreal, Canada, H2L 4M1 | |
| Principal Investigator: Site Reference ID/Investigator# 67862 | |
| Site Reference ID/Investigator# 69893 | Recruiting |
| Montreal, Canada, H3T 1E2 | |
| Principal Investigator: Site Reference ID/Investigator# 69893 | |
| Site Reference ID/Investigator# 68902 | Recruiting |
| Quebec City, Canada, G1S 4L8 | |
| Principal Investigator: Site Reference ID/Investigator# 68902 | |
| Site Reference ID/Investigator# 77373 | Recruiting |
| Toronto, Canada | |
| Principal Investigator: Site Reference ID/Investigator# 77373 | |
| Czech Republic | |
| Site Reference ID/Investigator# 65170 | Recruiting |
| Brno, Czech Republic, 656 53 | |
| Principal Investigator: Site Reference ID/Investigator# 65170 | |
| Site Reference ID/Investigator# 63923 | Recruiting |
| Olomouc, Czech Republic, 775 20 | |
| Principal Investigator: Site Reference ID/Investigator# 63923 | |
| Site Reference ID/Investigator# 65172 | Recruiting |
| Prague 2, Czech Republic, 12808 | |
| Principal Investigator: Site Reference ID/Investigator# 65172 | |
| Denmark | |
| Site Reference ID/Investigator# 67822 | Recruiting |
| Copenhagen, Denmark, 2100 | |
| Principal Investigator: Site Reference ID/Investigator# 67822 | |
| Site Reference ID/Investigator# 65173 | Recruiting |
| Vejle, Denmark, 7100 | |
| Principal Investigator: Site Reference ID/Investigator# 65173 | |
| Finland | |
| Site Reference ID/Investigator# 63924 | Recruiting |
| Helsinki, Finland, 00180 | |
| Principal Investigator: Site Reference ID/Investigator# 63924 | |
| France | |
| Site Reference ID/Investigator# 63926 | Recruiting |
| Paris Cedex 05, France, 75248 | |
| Principal Investigator: Site Reference ID/Investigator# 63926 | |
| Hungary | |
| Site Reference ID/Investigator# 65179 | Recruiting |
| Budapest, Hungary, 1106 | |
| Principal Investigator: Site Reference ID/Investigator# 65179 | |
| Site Reference ID/Investigator# 65178 | Recruiting |
| Debrecen, Hungary, 4032 | |
| Principal Investigator: Site Reference ID/Investigator# 65178 | |
| Site Reference ID/Investigator# 63928 | Recruiting |
| Szolnok, Hungary, 5004 | |
| Principal Investigator: Site Reference ID/Investigator# 63928 | |
| Israel | |
| Site Reference ID/Investigator# 65180 | Recruiting |
| Be'er-Sheva, Israel, 84802 | |
| Principal Investigator: Site Reference ID/Investigator# 65180 | |
| Site Reference ID/Investigator# 63930 | Recruiting |
| Haifa, Israel, 31096 | |
| Principal Investigator: Site Reference ID/Investigator# 63930 | |
| Site Reference ID/Investigator# 63931 | Recruiting |
| Jerusalem, Israel, 91120 | |
| Principal Investigator: Site Reference ID/Investigator# 63931 | |
| Site Reference ID/Investigator# 63929 | Recruiting |
| Petach Tikva, Israel, 49100 | |
| Principal Investigator: Site Reference ID/Investigator# 63929 | |
| Site Reference ID/Investigator# 63933 | Recruiting |
| Rehovot, Israel, 76100 | |
| Principal Investigator: Site Reference ID/Investigator# 63933 | |
| Site Reference ID/Investigator# 63932 | Recruiting |
| Tel Hashomer, Israel | |
| Principal Investigator: Site Reference ID/Investigator# 63932 | |
| Site Reference ID/Investigator# 65181 | Recruiting |
| Zerifin, Israel, 70300 | |
| Principal Investigator: Site Reference ID/Investigator# 65181 | |
| Norway | |
| Site Reference ID/Investigator# 67982 | Recruiting |
| Bergen, Norway, N-5021 | |
| Principal Investigator: Site Reference ID/Investigator# 67982 | |
| Poland | |
| Site Reference ID/Investigator# 73393 | Recruiting |
| Bydgoszcz, Poland, 85-796 | |
| Principal Investigator: Site Reference ID/Investigator# 73393 | |
| Site Reference ID/Investigator# 71060 | Recruiting |
| Olsztyn, Poland, 10513 | |
| Principal Investigator: Site Reference ID/Investigator# 71060 | |
| Site Reference ID/Investigator# 71061 | Recruiting |
| Poznan, Poland, 61-866 | |
| Principal Investigator: Site Reference ID/Investigator# 71061 | |
| Site Reference ID/Investigator# 68102 | Recruiting |
| Poznan, Poland, 61-485 | |
| Principal Investigator: Site Reference ID/Investigator# 68102 | |
| Russian Federation | |
| Site Reference ID/Investigator# 63938 | Recruiting |
| Chelyabinsk, Russian Federation, 454087 | |
| Principal Investigator: Site Reference ID/Investigator# 63938 | |
| Site Reference ID/Investigator# 65263 | Recruiting |
| Moscow, Russian Federation, 115478 | |
| Principal Investigator: Site Reference ID/Investigator# 65263 | |
| Site Reference ID/Investigator# 65264 | Recruiting |
| Pyatigorsk, Russian Federation, 357502 | |
| Principal Investigator: Site Reference ID/Investigator# 65264 | |
| Site Reference ID/Investigator# 65265 | Recruiting |
| St. Petersburg, Russian Federation, 197022 | |
| Principal Investigator: Site Reference ID/Investigator# 65265 | |
| Site Reference ID/Investigator# 65269 | Recruiting |
| St. Petersburg, Russian Federation, 197758 | |
| Principal Investigator: Site Reference ID/Investigator# 65269 | |
| Site Reference ID/Investigator# 78973 | Recruiting |
| St. Petersburg, Russian Federation, 197758 | |
| Principal Investigator: Site Reference ID/Investigator# 78973 | |
| Slovakia | |
| Site Reference ID/Investigator# 65274 | Recruiting |
| Nitra, Slovakia, 94911 | |
| Principal Investigator: Site Reference ID/Investigator# 65274 | |
| Ukraine | |
| Site Reference ID/Investigator# 63940 | Recruiting |
| Dnepropetrovsk, Ukraine, 49102 | |
| Principal Investigator: Site Reference ID/Investigator# 63940 | |
| Site Reference ID/Investigator# 63941 | Recruiting |
| Lviv, Ukraine, 79031 | |
| Principal Investigator: Site Reference ID/Investigator# 63941 | |
| Site Reference ID/Investigator# 65278 | Recruiting |
| Odessa, Ukraine, 65009 | |
| Principal Investigator: Site Reference ID/Investigator# 65278 | |
| Site Reference ID/Investigator# 65280 | Recruiting |
| Sumy, Ukraine, 40005 | |
| Principal Investigator: Site Reference ID/Investigator# 65280 | |
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
| Study Director: | Stacie P. Shepherd, MD | AbbVie |
More Information
No publications provided
| Responsible Party: | AbbVie ( AbbVie (prior sponsor, Abbott) ) |
| ClinicalTrials.gov Identifier: | NCT01506609 History of Changes |
| Other Study ID Numbers: | M12-895, 2011-002913-12 |
| Study First Received: | January 6, 2012 |
| Last Updated: | April 4, 2013 |
| Health Authority: | United States: Food and Drug Administration Brazil: Ministry of Health Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica Australia: Department of Health and Ageing Therapeutic Goods Administration Denmark: Danish Medicines Agency Finland: Ministry of Social Affairs and Health France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Hungary: National Institute of Pharmacy Czech Republic: State Institute for Drug Control Slovakia: State Institute for Drug Control Canada: Health Canada Russia: Ministry of Health of the Russian Federation Israel: Ministry of Health Norway: Norwegian Medicines Agency Poland: Ministry of Health Ukraine: Ministry of Health |
Keywords provided by AbbVie:
|
Temodal ABT-888 Carboplatin TMZ Temodar PARP temozolomide Paclitaxel |
Recurrent breast cancer Breast cancer Metastatic breast cancer BRCA2 mutation carrier BRCA1 mutation carrier veliparib Locally recurrent |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Temozolomide Dacarbazine Carboplatin Paclitaxel Antineoplastic Agents, Alkylating |
Alkylating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Tubulin Modulators Antimitotic Agents Mitosis Modulators Antineoplastic Agents, Phytogenic |
ClinicalTrials.gov processed this record on May 16, 2013